Document is current
Any future updates will be listed below
-
Authors
Bear, Harry D https://orcid.org/0000-0002-7632-9019
Deng, Xiaoyan
Bandyopadhyay, Dipankar
Idowu, Michael
Jenkins, Taylor M
Kmieciak, Maciej
Williams, Monique
Archer, Giovanni
Gwaltney, Lindsey
Dillon, Patrick
Flora, Daniel
Stover, Daniel https://orcid.org/0000-0001-9003-8165
Poklepovic, Andrew S
Hackney, Mary
Ross, Masey
Vachhani, Hetal
Louie, Raphael
McGuire, Kandace P
Grover, Amelia
Rahman, Tasnim
Hendrix, Amber
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02957968 at ClinicalTrials.govnct02957968 at ClinicalTrials.govDocuments that mention this clinical trial
T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy
https://doi.org/10.1136/jitc-2024-010294
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
nct02957968 at ClinicalTrials.govDocuments that mention this clinical trial
T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy
https://doi.org/10.1136/jitc-2024-010294
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
nct02957968 at ClinicalTrials.govDocuments that mention this clinical trial
T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy
https://doi.org/10.1136/jitc-2024-010294
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
nct05673200 at ClinicalTrials.govDocuments that mention this clinical trial
T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy
https://doi.org/10.1136/jitc-2024-010294
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
nct05673200 at ClinicalTrials.govDocuments that mention this clinical trial
T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy
https://doi.org/10.1136/jitc-2024-010294
Documents that mention this clinical trial
T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy
https://doi.org/10.1136/jitc-2024-010294
-
Funding
Funding for this research was provided by:
National Cancer Institute (P30 CA016059)
MSD Sharp and Dohme (N/A)
Commonwealth Foundation for Cancer Research Foundation (N/A)
- License Information
